{"count": 11, "results": [{"_id": "34719004", "pmid": 34719004, "pmcid": "PMC8557102", "title": "Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical trial", "journal": "Daru", "authors": ["Alipour S", "Rastad H", "Saberi A", "Faiz F", "Maleki-Hajiagha A", "Abedi M"], "date": "2021-12-01T00:00:00Z", "doi": "10.1007/s40199-021-00424-6", "meta_date_publication": "2021 Dec", "meta_volume": "29", "meta_issue": "2", "meta_pages": "389-396", "score": 50288.773, "text_hl": "Thus, we investigated @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ as a management strategy for @<m>DISEASE_Idiopathic_Pulmonary_Fibrosis</m> @DISEASE_MESH:D054990 @@@FCD@@@.", "citations": {"NLM": "Alipour S, Rastad H, Saberi A, Faiz F, Maleki-Hajiagha A, Abedi M. Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical trial Daru. 2021 Dec;29(2):389-396. PMID: 34719004", "BibTeX": "@article{34719004, title={Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical trial}, author={Alipour S and Rastad H and Saberi A and Faiz F and Maleki-Hajiagha A and Abedi M}, journal={Daru}, volume={29}, number={2}, pages={389-396}}"}}, {"_id": "35410255", "pmid": 35410255, "pmcid": "PMC9004115", "title": "Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis", "journal": "Respir Res", "authors": ["Teague TT", "Payne SR", "Kelly BT", "Dempsey TM", "McCoy RG", "Sangaralingham LR", "Limper AH"], "date": "2022-04-11T00:00:00Z", "doi": "10.1186/s12931-022-02001-0", "meta_date_publication": "2022 Apr 11", "meta_volume": "23", "meta_issue": "1", "meta_pages": "91", "score": 50281.41, "text_hl": "@SPECIES_9606 @@@Patients@@@ with @<m>DISEASE_Idiopathic_Pulmonary_Fibrosis</m> @DISEASE_MESH:D054990 @@@IPF@@@ were divided into those treated with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and those not treated with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, as seen in Fig. 1. ", "citations": {"NLM": "Teague TT, Payne SR, Kelly BT, Dempsey TM, McCoy RG, Sangaralingham LR, Limper AH. Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis Respir Res. 2022 Apr 11;23(1):91. PMID: 35410255", "BibTeX": "@article{35410255, title={Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis}, author={Teague TT and Payne SR and Kelly BT and Dempsey TM and McCoy RG and Sangaralingham LR and Limper AH}, journal={Respir Res}, volume={23}, number={1}, pages={91}}"}}, {"_id": "38286745", "pmid": 38286745, "pmcid": "PMC10794892", "title": "Metformin enhanced the effect of pirfenidone on pulmonary fibrosis in mice", "journal": "Clin Respir J", "authors": ["Liu N", "Song Y", "Liu T", "Wang H", "Yu N", "Ma H"], "date": "2024-01-01T00:00:00Z", "doi": "10.1111/crj.13731", "meta_date_publication": "2024 Jan", "meta_volume": "18", "meta_issue": "1", "meta_pages": "e13731", "score": 50261.836, "text_hl": "Moreover, these findings provide an experimental basis for examining whether @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ can improve the antifibrotic effects of @CHEMICAL_pirfenidone @CHEMICAL_MESH:C093844 @@@pirfenidone@@@ on @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Idiopathic_Pulmonary_Fibrosis</m> @DISEASE_MESH:D054990 @@@idiopathic pulmonary fibrosis@@@ (@<m>DISEASE_Idiopathic_Pulmonary_Fibrosis</m> @DISEASE_MESH:D054990 @@@IPF@@@). ", "citations": {"NLM": "Liu N, Song Y, Liu T, Wang H, Yu N, Ma H. Metformin enhanced the effect of pirfenidone on pulmonary fibrosis in mice Clin Respir J. 2024 Jan;18(1):e13731. PMID: 38286745", "BibTeX": "@article{38286745, title={Metformin enhanced the effect of pirfenidone on pulmonary fibrosis in mice}, author={Liu N and Song Y and Liu T and Wang H and Yu N and Ma H}, journal={Clin Respir J}, volume={18}, number={1}, pages={e13731}}"}}, {"_id": "32471963", "pmid": 32471963, "title": "The concentration-dependent pro-fibrotic effect of metformin on LPS and high glucose induced fibroblast NIH 3T3 and Macrophage RAW 264.7 Cell co-culture.", "journal": "Med J Malaysia", "authors": ["Awaluddin R", "Nugrahaningsih DAA", "Solikhah EN"], "date": "2020-05-01T00:00:00Z", "meta_date_publication": "2020 May", "meta_volume": "75", "meta_issue": "Suppl 1", "meta_pages": "10-13", "score": 50257.61, "text_hl": "However, the benefit of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ therapy in @<m>DISEASE_Idiopathic_Pulmonary_Fibrosis</m> @DISEASE_MESH:D054990 @@@IPF@@@ is still controversial. ", "citations": {"NLM": "Awaluddin R, Nugrahaningsih DAA, Solikhah EN. The concentration-dependent pro-fibrotic effect of metformin on LPS and high glucose induced fibroblast NIH 3T3 and Macrophage RAW 264.7 Cell co-culture. Med J Malaysia. 2020 May;75(Suppl 1):10-13. PMID: 32471963", "BibTeX": "@article{32471963, title={The concentration-dependent pro-fibrotic effect of metformin on LPS and high glucose induced fibroblast NIH 3T3 and Macrophage RAW 264.7 Cell co-culture.}, author={Awaluddin R and Nugrahaningsih DAA and Solikhah EN}, journal={Med J Malaysia}, volume={75}, number={Suppl 1}, pages={10-13}}"}}, {"_id": "37077349", "pmid": 37077349, "pmcid": "PMC10106576", "title": "Drugs against metabolic diseases as potential senotherapeutics for aging-related respiratory diseases", "journal": "Front Endocrinol (Lausanne)", "authors": ["Matsubayashi S", "Ito S", "Araya J", "Kuwano K"], "date": "2023-04-03T00:00:00Z", "doi": "10.3389/fendo.2023.1079626", "meta_date_publication": "2023", "meta_volume": "14", "meta_issue": "", "meta_pages": "1079626", "score": 50252.074, "text_hl": "Several studies have demonstrated the potential efficacy of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in treating @<m>DISEASE_Idiopathic_Pulmonary_Fibrosis</m> @DISEASE_MESH:D054990 @@@IPF@@@. ", "citations": {"NLM": "Matsubayashi S, Ito S, Araya J, Kuwano K. Drugs against metabolic diseases as potential senotherapeutics for aging-related respiratory diseases Front Endocrinol (Lausanne). 2023;14():1079626. PMID: 37077349", "BibTeX": "@article{37077349, title={Drugs against metabolic diseases as potential senotherapeutics for aging-related respiratory diseases}, author={Matsubayashi S and Ito S and Araya J and Kuwano K}, journal={Front Endocrinol (Lausanne)}, volume={14}, pages={1079626}}"}}, {"_id": "39642371", "pmid": 39642371, "title": "Targeting the Epigenetic Regulator CBX5 Promotes Fibroblast Metabolic Reprogramming and Inhibits Lung Fibrosis.", "journal": "Am J Respir Cell Mol Biol", "authors": ["Hong J", "Pham TX", "Lee J", "Raslan AA", "Nicolas K", "Sharov A", "Meridew JA", "Urrutia RA", "Lomberk G", "Huang SK", "Ligresti G"], "date": "2024-12-06T00:00:00Z", "doi": "10.1165/rcmb.2024-0255OC", "meta_date_publication": "2024 Dec 6", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50246.344, "text_hl": "Finally, interruption of the @GENE_CBX5 @GENE_23468 @@@CBX5@@@ pathway in @<m>DISEASE_Idiopathic_Pulmonary_Fibrosis</m> @DISEASE_MESH:D054990 @@@IPF@@@ fibroblasts in vitro and in @<m>DISEASE_Idiopathic_Pulmonary_Fibrosis</m> @DISEASE_MESH:D054990 @@@IPF@@@ lung explants ex vivo synergistically potentiated @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@-induced @GENE_PRKAA1 @GENE_5562 @@@AMPK@@@ activation and inhibited collagen secretion. ", "citations": {"NLM": "Hong J, Pham TX, Lee J, Raslan AA, Nicolas K, Sharov A, Meridew JA, Urrutia RA, Lomberk G, Huang SK, Ligresti G. Targeting the Epigenetic Regulator CBX5 Promotes Fibroblast Metabolic Reprogramming and Inhibits Lung Fibrosis. Am J Respir Cell Mol Biol. 2024 Dec 6;():. PMID: 39642371", "BibTeX": "@article{39642371, title={Targeting the Epigenetic Regulator CBX5 Promotes Fibroblast Metabolic Reprogramming and Inhibits Lung Fibrosis.}, author={Hong J and Pham TX and Lee J and Raslan AA and Nicolas K and Sharov A and Meridew JA and Urrutia RA and Lomberk G and Huang SK and Ligresti G}, journal={Am J Respir Cell Mol Biol}}"}}, {"_id": "27576730", "pmid": 27576730, "pmcid": "PMC5006432", "title": "Metformin attenuates lung fibrosis development via NOX4 suppression", "journal": "Respir Res", "authors": ["Sato N", "Takasaka N", "Yoshida M", "Tsubouchi K", "Minagawa S", "Araya J", "Saito N", "Fujita Y", "Kurita Y", "Kobayashi K", "Ito S", "Hara H", "Kadota T", "Yanagisawa H", "Hashimoto M", "Utsumi H", "Wakui H", "Kojima J", "Numata T", "Kaneko Y", "Odaka M", "Morikawa T", "Nakayama K", "Kohrogi H", "Kuwano K"], "date": "2016-08-30T00:00:00Z", "doi": "10.1186/s12931-016-0420-x", "meta_date_publication": "2016 Aug 30", "meta_volume": "17", "meta_issue": "1", "meta_pages": "107", "score": 50077.5, "text_hl": "These findings suggest that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ can be a promising anti-fibrotic modality of treatment for @<m>DISEASE_Idiopathic_Pulmonary_Fibrosis</m> @DISEASE_MESH:D054990 @@@IPF@@@ affected by @GENE_TGFB1 @GENE_7040 @@@TGF-beta@@@.", "citations": {"NLM": "Sato N, Takasaka N, Yoshida M, Tsubouchi K, Minagawa S, Araya J, Saito N, Fujita Y, Kurita Y, Kobayashi K, Ito S, Hara H, Kadota T, Yanagisawa H, Hashimoto M, Utsumi H, Wakui H, Kojima J, Numata T, Kaneko Y, Odaka M, Morikawa T, Nakayama K, Kohrogi H, Kuwano K. Metformin attenuates lung fibrosis development via NOX4 suppression Respir Res. 2016 Aug 30;17(1):107. PMID: 27576730", "BibTeX": "@article{27576730, title={Metformin attenuates lung fibrosis development via NOX4 suppression}, author={Sato N and Takasaka N and Yoshida M and Tsubouchi K and Minagawa S and Araya J and Saito N and Fujita Y and Kurita Y and Kobayashi K and Ito S and Hara H and Kadota T and Yanagisawa H and Hashimoto M and Utsumi H and Wakui H and Kojima J and Numata T and Kaneko Y and Odaka M and Morikawa T and Nakayama K and Kohrogi H and Kuwano K}, journal={Respir Res}, volume={17}, number={1}, pages={107}}"}}, {"_id": "28598826", "pmid": 28598826, "title": "The evaluation of the effect of metformin on breast fibrocystic disease.", "journal": "Breast Dis", "authors": ["Talaei A", "Moradi A", "Rafiei F"], "date": "2017-01-01T00:00:00Z", "doi": "10.3233/BD-160256", "meta_date_publication": "2017", "meta_volume": "37", "meta_issue": "2", "meta_pages": "49-53", "score": 50074.82, "text_hl": "The evaluation of the effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on @DISEASE_Hereditary_Breast_and_Ovarian_Cancer_Syndrome @DISEASE_MESH:D061325 @@@breast@@@ @<m>DISEASE_Idiopathic_Pulmonary_Fibrosis</m> @DISEASE_MESH:D054990 @@@fibrocystic disease@@@.", "citations": {"NLM": "Talaei A, Moradi A, Rafiei F. The evaluation of the effect of metformin on breast fibrocystic disease. Breast Dis. 2017;37(2):49-53. PMID: 28598826", "BibTeX": "@article{28598826, title={The evaluation of the effect of metformin on breast fibrocystic disease.}, author={Talaei A and Moradi A and Rafiei F}, journal={Breast Dis}, volume={37}, number={2}, pages={49-53}}"}}, {"_id": "30007987", "pmid": 30007987, "title": "Metformin in Idiopathic Pulmonary Fibrosis \"Seeking the Holy-Grail through Drug-Repositioning\".", "journal": "Respiration", "authors": ["Tzouvelekis A", "Tzilas V", "Dassiou M", "Bouros D"], "date": "2018-01-01T00:00:00Z", "doi": "10.1159/000490917", "meta_date_publication": "2018", "meta_volume": "96", "meta_issue": "4", "meta_pages": "305-307", "score": 50072.418, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ in @<m>DISEASE_Idiopathic_Pulmonary_Fibrosis</m> @DISEASE_MESH:D054990 @@@Idiopathic Pulmonary Fibrosis@@@ \"Seeking the Holy-Grail through Drug-Repositioning\".", "citations": {"NLM": "Tzouvelekis A, Tzilas V, Dassiou M, Bouros D. Metformin in Idiopathic Pulmonary Fibrosis \"Seeking the Holy-Grail through Drug-Repositioning\". Respiration. 2018;96(4):305-307. PMID: 30007987", "BibTeX": "@article{30007987, title={Metformin in Idiopathic Pulmonary Fibrosis \"Seeking the Holy-Grail through Drug-Repositioning\".}, author={Tzouvelekis A and Tzilas V and Dassiou M and Bouros D}, journal={Respiration}, volume={96}, number={4}, pages={305-307}}"}}, {"_id": "30025392", "pmid": 30025392, "title": "Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis.", "journal": "Respiration", "authors": ["Spagnolo P", "Kreuter M", "Maher TM", "Wuyts W", "Bonella F", "Corte TJ", "Kopf S", "Weycker D", "Kirchgaessler KU", "Ryerson CJ"], "date": "2018-01-01T00:00:00Z", "doi": "10.1159/000489668", "meta_date_publication": "2018", "meta_volume": "96", "meta_issue": "4", "meta_pages": "314-322", "score": 50069.96, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Does Not Affect Clinically Relevant Outcomes in @SPECIES_9606 @@@Patients@@@ with @<m>DISEASE_Idiopathic_Pulmonary_Fibrosis</m> @DISEASE_MESH:D054990 @@@Idiopathic Pulmonary Fibrosis@@@.", "citations": {"NLM": "Spagnolo P, Kreuter M, Maher TM, Wuyts W, Bonella F, Corte TJ, Kopf S, Weycker D, Kirchgaessler KU, Ryerson CJ. Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis. Respiration. 2018;96(4):314-322. PMID: 30025392", "BibTeX": "@article{30025392, title={Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis.}, author={Spagnolo P and Kreuter M and Maher TM and Wuyts W and Bonella F and Corte TJ and Kopf S and Weycker D and Kirchgaessler KU and Ryerson CJ}, journal={Respiration}, volume={96}, number={4}, pages={314-322}}"}}]}